EVK Share Price Performance
€13.94
-7.19 (-34.03%)
29.9% undervalued intrinsic discount
€19.90
Fair Value
Price €13.94
AnalystHighTarget €19.90
AnalystLowTarget €12.20
AnalystConsensusTarget €14.60
Fair Value€19.90
Share Pricen/a
Evonik Industries AG Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 38 Fair Values set on narratives written by author
EVK Community Narratives
AN
Fair Value €19.9 29.9% undervalued intrinsic discount
Circular Economy And Decarbonization Trends Will Unlock Specialty Markets
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value €12.2 14.3% overvalued intrinsic discount
Rising EU Pressure And Market Shifts Will Squeeze Margins
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value €14.6 4.5% undervalued intrinsic discount
Analyst Views Mixed as Evonik Faces Softer Outlook Amid Valuation Adjustments and Strategic Moves
0users have liked this narrative
0users have commented on this narrative
24users have followed this narrative
Circular Economy And Decarbonization Trends Will Unlock Specialty Markets
Key Takeaways Aggressive cost-saving initiatives and digital transformation are set to drive lasting margin expansion, with management guiding for significantly higher-than-expected operational efficiency gains. Strategic focus on sustainable technologies and resilient production supports robust earnings growth, with premium revenue opportunities unlocking across healthcare, nutrition, and green specialty chemicals.Read more
43
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
€19.9
29.9% undervalued intrinsic discount
Fair Value
Revenue
2.3% p.a.
Profit Margin
3.69%
Future PE
20.05x
Price in 2029
€23.91
Rising EU Pressure And Market Shifts Will Squeeze Margins
Key Takeaways Rising regulatory costs, required environmental upgrades, and green competition threaten Evonik's margins and long-term profitability. Dependence on shrinking European markets and intensified low-cost competition limit growth prospects and erode pricing power.Read more
42
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
€12.2
14.3% overvalued intrinsic discount
Fair Value
Revenue
0.91% p.a.
Profit Margin
3.61%
Future PE
13.22x
Price in 2029
€14.71
Analyst Views Mixed as Evonik Faces Softer Outlook Amid Valuation Adjustments and Strategic Moves
Key Takeaways Aggressive cost optimization and a shift to specialty chemicals are set to strengthen margins and align with rising demand for sustainable solutions. Expanded production in key plants and focus on healthcare, nutrition, and biopharma position the company for stable growth aided by regulatory and demographic trends.Read more
214
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
24users have followed this narrative
AN
€14.6
4.5% undervalued intrinsic discount
Fair Value
Revenue
1.08% p.a.
Profit Margin
3.3%
Future PE
16.1x
Price in 2029
€17.57
Trending Discussion
Recently Updated Narratives
AN
EVK: Margin Resilience And Lower Discount Rate Will Support Medium-Term Re Rating Potential
Fair Value: €19.9 29.9% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
EVK: Weaker Pricing Power Will Limit Earnings Delivery Despite Mixed Broker Views
Fair Value: €12.2 14.3% overvalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
EVK: Sector Caution And Margin Execution Will Shape Future Upside Potential
Fair Value: €14.6 4.5% undervalued intrinsic discount
24 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Evonik Industries AG Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
May 08, 2026
- 0.57
- 24.59%
- 1.88%
- 36.8%
About EVK
- Founded
- 1847
- Employees
- 29852
- CEO
- WebsiteView website
Evonik Industries AG operates as a chemicals company in the Asia-Pacific, Europe, the Middle East, Africa, and the Americas. It operates through the Advanced Technologies, Custom Solutions, and Infrastructure segments. The Advanced Technologies segment provides polymers for medical applications; crosslinkers; hydrogen peroxide, a sterilizing agent for cleaning silicon wafers and a bleaching agent for the paper and textile industries; fumed and precipitated silicas and silanes for the automotive, tire, electronics, and cosmetics industries; and D-/L-methionine and lysine for animal nutrition. Its Custom Solutions segment provides additives for coatings, adhesives, sealants, polyurethane foams, and lubricants for the cosmetic, cleaning, and pharmaceutical industries. The Infrastructure segment engages in the infrastructure activities and offers butadiene, MTBE, butene-1, isononanol, and DINP for use in the plastic and packaging industries, production of rubber and fuels, and as plasticizers in the construction and automotive sectors. The company was founded in 1847 and is headquartered in Essen, Germany.
